跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
LYSODREN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
LYSODREN
Authorized
STANDARD
LYSODREN
HRA Pharma Rare Diseases SAS
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
aea725586b11fa69
Company
HRA Pharma Rare Diseases SAS
Type
Standard
Approval Details
Approval Id
aea725586b11fa69
Drug Approval Canada Name
LYSODREN
Product Name
LYSODREN
Status
Marketed
Status Date
2021-02-03
Original Market Date
1979-12-31
Din
00463221
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01XX23 MITOTANE
Atc Name
l 01 xx 23
Aig Number
0113395001
Company Name
HRA Pharma Rare Diseases SAS
Company Address
200 Avenue De Paris, Chatillon, Hauts-De-Seine, France, 92320
Company Detail Path
/organization/hra-pharma-rare-diseases-sas
Company Information
Pharmaceutical Company Name
HRA Pharma Rare Diseases SAS
Country Name
France
Website
http://www.hra-pharma-rare-diseases.com
Active Ingredients
MITOTANE
500 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
aea725586b11fa69
Type
Standard
Back to Health Canada Approvals